VRTX241108C290000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
TSLA Up, China Down, Friday Market Quiet After Loud, Decisive Week | Live Stock
FOMC Cut Sends Prices Up, Election Blitz Strong | Wall Street Today
Market Hits All-Time Highs on FOMC Rate Day | Live Stock
Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
Market Prices in Trump Victory with Index Records | Wall Street Today
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Market Trumps Past Records Wednesday Afternoon | Live Stock
Vertex Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $408
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $486 to $600
Vertex Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Vertex Pharmaceuticals: Strong Financial Performance and Innovative Drug Pipeline Underpin Buy Rating
Cautious Outlook: Evaluating Vertex Pharmaceuticals' Growth Potential Amidst Strong Performance and Speculative Risks
Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Tuesday Market Closed Up, with Presidency in Sight | Wall Street Today
Vertex Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity